A Multi Gene Targeting Approach to Treating Liver Diseases with Metadichol

Abstract

Liver diseases are becoming a major health concern. In the developing countries it is due to microbial infection. In the rest of the developed world it is due to alcohol abuse. Chronic liver disease and cirrhosis are a significant health concern in western countries. It is the fifth most common cause of death, after heart disease, cancer, stroke, and chest disease. The liver is capable of regeneration, but it can be overwhelmed leading to liver diseases like cirrhosis and hepatocellular cancer (HCC).

Vitamin D levels are low in most patients with liver diseases, and this suggests possible therapeutic benefits with use of vitamin D or its analogues. Vitamin D, through the vitamin D nuclear-40 receptor (VDR) plays a crucial role in mineral ion homeostasis. The liver is central in vitamin D synthesis and there is a need for an agent that will not lead to hypercalcemia. Metadichol, a nano emulsion of long-chain alcohols derived from food, is an inverse agonist of Vitamin D.

Introduction

Liver diseases are a worldwide problem. The number of drugs for treating liver diseases is small in number. There is a need for a safe and therapeutic treatment with new molecular entities.

The liver helps purify the blood. It produces albumin as well as the proteins that cause blood clotting. The liver stores sugar appropriately, fats and vitamins until they are needed elsewhere in the body and also manufactures fat, cholesterol, and protein bilirubin. An inflamed liver does not perform these functions well, which brings about many of the symptoms, signs, and problems associated with any hepatitis.

Best Regards:
Veronica Thompson
Journal Manager
Journal of Cytokine Biology
Email:  cytokinebiol@oajournal.org